{"result": "(\"entity\"<|>GLUCONEOGENESIS<|>EVENT<|>Gluconeogenesis is the metabolic process that generates glucose from non-carbohydrate substrates, which compensates for the insufficient glycogenolysis in GSDIII patients.)\n##\n(\"entity\"<|>HIPERTRIGLICERIDEMIA<|>EVENT<|>Hipertrigliceridemia is a condition characterized by elevated levels of triglycerides in the blood, commonly seen in GSDIII patients.)\n##\n(\"entity\"<|>GASTROSTOMÍA<|>EVENT<|>Gastrostomía is a surgical procedure to create an opening into the stomach, recommended for patients requiring prolonged enteral nutrition in GSDIII.)\n##\n(\"entity\"<|>YEYUNOSTOMÍA<|>EVENT<|>Yeyunostomía is a surgical procedure to create an opening into the jejunum, also used for enteral feeding in GSDIII patients.)\n##\n(\"relationship\"<|>GSDIII<|>GLUCONEOGENESIS<|>Gluconeogenesis helps to maintain blood glucose levels in GSDIII patients despite impaired glycogenolysis<|>8)\n##\n(\"relationship\"<|>GSDIII<|>HIPERTRIGLICERIDEMIA<|>Hipertrigliceridemia is a common metabolic complication associated with GSDIII<|>7)\n##\n(\"relationship\"<|>GSDIII<|>GASTROSTOMÍA<|>Gastrostomía may be necessary for GSDIII patients who require long-term nutritional support<|>6)\n##\n(\"relationship\"<|>GSDIII<|>YEYUNOSTOMÍA<|>Yeyunostomía may be performed for enteral feeding in GSDIII patients needing prolonged nutritional support<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ificación tiene las siguientes consecuencias:\n\n- Se acumulan en el hígado polisacáridos ramificados (dextrina límite) que producen hepatomegalia y posteriormente esplenomegalia secundaria.\n- La interrupción de la glucogenólisis condiciona una disminución de la liberación de glucosa al torrente circulatorio con la consecuente hipoglucemia, que es la manifestación principal en estos pacientes. Sin embargo, estas hipoglucemias son menos graves que en la GSDI, ya que la insuficiente glucogenólisis es compensada con el aumento de la gluconeogénesis, que sí es efectiva (a diferencia de la GSDI, los residuos de glucosa pueden ser liberados al plasma, pues la actividad G6Pasa está conservada). Al afectarse la glucogenólisis también aparece cetosis; sin embargo, no se produce hiperlactacidemia, ya que no se sintetiza suficiente Glu-6-P, sustrato que en exceso se deriva hacia esta vía, como sucede en la GSDI.\n\n### 1.2.4. Soporte nutricional artificial\n\nSe administrará nutrición enteral nocturna en niños pequeños tras la finalización de la lactancia y todos aquellos pacientes que no mantengan niveles de glucemia con una dosis de almidón de maíz antes de acostarse. Se puede utilizar una infusión de glucosa o de polímeros de glucosa, o una fórmula enteral polimérica comercial sin lactosa ni fructosa. No debe comenzarse después de 1 hora tras la última ingesta ni suspenderse más de 15-30 minutos antes del desayuno. Así mismo se debe estar atento a las desconexiones o interrupciones accidentales de la perfusión durante la noche ya que se puede producir una hipoglucemia severa. Dada la necesidad prolongada de aporte nocturno de glucosa, se aconseja realizar un acceso enteral permanente en forma de gastrostomía o yeyunostomía.\n\nPara calcular las necesidades de glucosa se tendrá en cuenta la tasa de producción endógena estimada según la edad (tabla 2). En lactantes se recomienda iniciar con un aporte de 7 mg/kg/min y posteriormente ajustar a la baja si es posible según glucemias.\n\nEn niños mayores, tras el cálculo inicial también se intentará ir disminuyendo (4-6 mg/kg/min) para mantener glucemias entre 70-95 mg/dl. En adolescentes suele ser suficiente con 2 mg/kg/min de glucosa si es que aún precisan soporte enteral nocturno.\n\n### 1.3. Déficit de amilo-1,6-glucosidasa, glucogenosis tipo III o enfermedad de Cori (GSDIII)\n\n#### 1.3.1. Fisiopatología y diagnóstico\n\nLa GSDIII constituye un grupo de patologías producidas por la afectación de alguna de las isoformas de la enzima desramificadora del glucógeno amilo-1,6-glucosidasa (gen AGL, 1p21.2). Su incidencia estimada es de 1:100.000. Existen dos isoformas de la enzima, hepática y muscular, y se diferencian cuatro subtipos de la enfermedad:\n\n- IIIa: Déficit de las isoformas hepática y muscular (85%).\n- IIIb: Déficit exclusivo de la isoforma hepática (15%).\n- IIIc: Déficit de la actividad glucosidasa de la enzima desramificadora (extremadamente rara).\n- IIId: Déficit de la actividad transferasa de la enzima desramificadora (extremadamente rara).\n\nLas manifestaciones clínicas son variables tanto en los órganos afectados, en función del subtipo que presente el paciente, como en la gravedad, que puede ir desde leve a severa. Los síntomas hepático-metabólicos son, en general, similares a la GSDI pero más leves, se toleran períodos de ayuno más prolongados (sobre todo a medida que avanza la edad) y el pronóstico es más favorable. Al igual que en la GSDI, los primeros síntomas aparecen en el primer año de vida (es raro en el período neonatal), con hepatomegalia (98%), hipoglucemia cetósica (53%), fallo de medro (49%) y dislipemia, sobre todo hipertrigliceridemia (>80% de pacientes, pero menos grave que en la GSDI), lo que hace de entrada indistinguibles ambas patologías. Con el paso de los años esta clínica mejora y habitualmente se normaliza tras la pubertad, debido a la disminución de los requerimientos de glucosa y a la fibrosis hepática, aunque es muy raro que ésta progrese a cirrosis. La aparición de adenomas hepáticos o hepatocarcinoma ocurre en menos del 10% de los pacientes, y también son infrecuentes la hiperuricemia y la afectación renal. Las complicaciones a largo plazo incluyen osteopenia/osteopor\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>GSDIII<|>EVENT<|>Glycogen Storage Disease Type III, also known as Cori disease, is a metabolic disorder caused by a deficiency of the enzyme amilo-1,6-glucosidase, leading to various clinical manifestations related to glycogen metabolism.)\n##\n(\"entity\"<|>AMILO-1,6-GLUCOSIDASA<|>ORGANIZATION<|>Amilo-1,6-glucosidasa is an enzyme responsible for glycogen breakdown, and its deficiency leads to GSDIII.)\n##\n(\"entity\"<|>GEN AGL<|>ORGANIZATION<|>The AGL gene located on chromosome 1p21.2 encodes the enzyme amilo-1,6-glucosidasa, and mutations in this gene cause GSDIII.)\n##\n(\"entity\"<|>HEPATOMEGALIA<|>EVENT<|>Hepatomegalia is the enlargement of the liver, commonly observed in patients with GSDIII.)\n##\n(\"entity\"<|>HIPOGLUCEMIA<|>EVENT<|>Hipo-glucemia refers to low blood sugar levels, a primary manifestation in patients with GSDIII.)\n##\n(\"entity\"<|>DISLIPIDEMIA<|>EVENT<|>Dislipidemia is an abnormal amount of lipids in the blood, often seen in GSDIII patients, particularly hypertriglyceridemia.)\n##\n(\"entity\"<|>FALLO DE MEDRO<|>EVENT<|>Fallo de medro refers to failure to thrive, a common symptom in children with GSDIII.)\n##\n(\"entity\"<|>CIRROSIS<|>EVENT<|>Cirrhosis is a late-stage liver disease that can occur in some patients with GSDIII, although it is rare.)\n##\n(\"relationship\"<|>GSDIII<|>AMILO-1,6-GLUCOSIDASA<|>GSDIII is caused by a deficiency of the enzyme amilo-1,6-glucosidasa<|>9)\n##\n(\"relationship\"<|>GSDIII<|>GEN AGL<|>Mutations in the AGL gene lead to the development of GSDIII<|>9)\n##\n(\"relationship\"<|>GSDIII<|>HEPATOMEGALIA<|>Hepatomegalia is a common clinical manifestation of GSDIII<|>8)\n##\n(\"relationship\"<|>GSDIII<|>HIPOGLUCEMIA<|>Hipo-glucemia is a primary symptom in patients with GSDIII<|>8)\n##\n(\"relationship\"<|>GSDIII<|>DISLIPIDEMIA<|>Dislipidemia, particularly hypertriglyceridemia, is often observed in GSDIII patients<|>7)\n##\n(\"relationship\"<|>GSDIII<|>FALLO DE MEDRO<|>Fallo de medro is a symptom that can occur in children with GSDIII<|>7)\n##\n(\"relationship\"<|>GSDIII<|>CIRROSIS<|>Cirrhosis can occur as a long-term complication in some patients with GSDIII, although it is rare<|>3)\n<|COMPLETE|>"}]}